Metacognitive Therapy, Fluvoxamine, or Combination Treatment in Obsessive-Compulsive Disorder: A randomized clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138811303372N1

Enrollment

Registered

2010-04-26

Start date

2009-09-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: pharmacotherapy(Fluvoxamine 50-300mg, daily, 10 weeks). Intervention 2: Metacognitive Therapy (10 weeks). Intervention 3: combination of metacognitive therapy and fluvoxamine(50-300ml

Treatment - Drugs

Behavior

pharmacotherapy(Fluvoxamine 50-300mg, daily, 10 weeks)

Metacognitive Therapy (10 weeks)

combination of metacognitive therapy and fluvoxamine(50-300ml daily,10 weeks)

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) diagnosis of OCD according to DSM-IV-TR, (2) duration of the illness for at least 1 year, (3) age between 18 to 50. Exclusion criteria: (1) currently suicidal or psychotic, (2)have a personality disorder, neurological disease or substance abuse problem and other comorbid axis I disorders, (3) have been receiving other psychological treatment or pharmacotherapy during the previous month.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Global functioning. Timepoint: before treatment, every two weeks for 3 months, every 6 months for one years in follow up. Method of measurement: Scale.;Obsessive-compulsive symptoms severity. Timepoint: before treatment, every two weeks for 3 months, every 6 months for one years in follow up. Method of measurement: scale.;Depression severity. Timepoint: before treatment, every two weeks for 3 months, every 6 months for one years in follow up. Method of measurement: Inventory.;Anxiety severity. Timepoint: before treatment, every two weeks for 3 months, every 6 months for one years in follow up. Method of measurement: Inventory.;Stress severity. Timepoint: before treatment, every two weeks for 3 months, every 6 months for one years in follow up. Method of measurement: Scale.;Subjective distress. Timepoint: before treatment, every two weeks for 3 months, every 6 months for one years in follow up. Method of measurement: Scale.	—

Measure

Time frame

Global functioning. Timepoint: before treatment, every two weeks for 3 months, every 6 months for one years in follow up. Method of measurement: Scale.;Obsessive-compulsive symptoms severity. Timepoint: before treatment, every two weeks for 3 months, every 6 months for one years in follow up. Method of measurement: scale.;Depression severity. Timepoint: before treatment, every two weeks for 3 months, every 6 months for one years in follow up. Method of measurement: Inventory.;Anxiety severity. Timepoint: before treatment, every two weeks for 3 months, every 6 months for one years in follow up. Method of measurement: Inventory.;Stress severity. Timepoint: before treatment, every two weeks for 3 months, every 6 months for one years in follow up. Method of measurement: Scale.;Subjective distress. Timepoint: before treatment, every two weeks for 3 months, every 6 months for one years in follow up. Method of measurement: Scale.

—

Secondary

Measure	Time frame
Metacognition components. Timepoint: before and after treatment. Method of measurement: inventory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Shareh

Iran University of Medical Sciences, Tehran Psychiatric Institute

h.shareh@stu.iums.ac.ir, hsharreh@gmail.com, hsharreh@yahoo.com.au+98 21 6655 1655

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026